Figure 1From: A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design Schematic diagram of the CRF Asian Study with Oral PGI 2 derivative for Evaluating Improvement of Renal function (CASSIOPEIR) study design. Back to article page